Immunition Oncology

Our oncolytic platform locates and infiltrates tumors in the body, and then enters into cancer cells, where it locally delivers one or more molecular therapies.

Our Mission

To eradicate cancer from the body at a late metastatic stage when prior therapies fail, and, in time, to interrupt cancer progression from occult, mutant or post-surgery remnant cancer cells.

Our firm introduces a multifunctional eukaryotic cellular platform that can integrate other molecular agents. Engineered cells deploy an integrated complex of therapeutic mechanisms to reach inside tumors, and destroy cancer cells, with intra-tumor production of payload agents.

CORE CHALLENGE - Solid cancers are complex diseases that are often difficult to detect, hard to reach, and well-protected. They also can recurr due to growth or mutation of resistant sub-types.

Tumors contain cancer cells that are diverse, with a tendency to mutate; that makes it very difficult to target all cancer cells of a tumor at a biomolecular level entirely, or even be able to use the same target(s) in future.
Cancer cells program their surroundings into an ecosystem that both protects them and promotes their development - the Tumor Microenvironment (TME).

OUR SOLUTION - a multifunctional platform of eukaryotic cells of Neospora caninum, a protozoan not pathogenic to humans. Neospora readily infiltrates and infects tumoral tissues, but is neutralized and eliminated from normal tissues. It is also an unequalled, high payload transgenetic delivery systems of complex, multiple molecular therapies.

Neospora locates tumors - Tumor tropism
It penetrate the tumor's physical barrier - Boring into the TME's Extracellular Matrix (ECM)
It infiltrates the TME's cells by - Intracellular invasion.
It reverses the TME immunorotective subversion of immune cells, and restores immune competency/susceptibility - Reprogram of TME & activation of Th1 response.
Enter into cancer cells, replicates, causing lysis, and spreads to other cells. Intracellular replication. oncolysis and release of neoantigens.
On-site bioproduction of therapeutic payload agents. Tumor-localized bioproduction of therapeutic molecules.

Page updated

Google Sites

Report abuse

Immunition Oncology

Our Mission

To eradicate cancer from the body at a late metastatic stage when prior therapies fail, and, in time, to interrupt cancer progression from occult, mutant or post-surgery remnant cancer cells.

Our firm introduces a multifunctional eukaryotic cellular platform that can integrate other molecular agents. Engineered cells deploy an integrated complex of therapeutic mechanisms to reach inside tumors, and destroy cancer cells, with intra-tumor production of payload agents.

CORE CHALLENGE - Solid cancers are complex diseases that are often difficult to detect, hard to reach, and well-protected. They also can recurr due to growth or mutation of resistant sub-types.

Tumors contain cancer cells that are diverse, with a tendency to mutate; that makes it very difficult to target all cancer cells of a tumor at a biomolecular level entirely, or even be able to use the same target(s) in future.

Cancer cells program their surroundings into an ecosystem that both protects them and promotes their development - the Tumor Microenvironment (TME).